Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine

Radiology

Volumn 230, Issue 1, 2004, Pages 55-64

  Knopp, Michael V ^a   Runge, Val M ^b   Essig, Marco ^c   Hartman, Marius ^d   Jansen, Olav ^e   Kirchin, Miles A ^f   Moeller, Albrecht ^g   Seeberg, Astrid H ^h   Lodemann, Klaus Peter ^h  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f Worldwide Medical Affairs   (Italy)

^g MEDIDATA GmbH   (Germany)

^h Bracco Altana Pharma   (Germany)

Author keywords

Brain neoplasms, MR; Gadolinium Magnetic resonance (MR), contrast media

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CROSSOVER PROCEDURE; FEMALE; GLIOMA; HUMAN; IMAGE ENHANCEMENT; IMAGING SYSTEM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR VASCULARIZATION;

ADULT; AGED; BRAIN NEOPLASMS; CONTRAST MEDIA; DOUBLE-BLIND METHOD; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS;

EID: 0346848756     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2301021085     Document Type: Article

References (40)

1. Yuh WT, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991; 180:485-491.
2. Valk J, Algra PR, Hazenberg CJ, Slooff WB, Slavand MG. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MR1 of the central nervous system. Neuroradiology 1993; 35:173-177.
3. Brugières P, Gaston A, Degryse HR, et al. Randomized double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 1994; 36:27-30.
4. Åkeson P, Jonsson E, Haugen I, Holtas S. Contrast-enhanced MR1 of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 1995; 37:229-233.
5. Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995; 30:75-78.
6. Grossman RI, Rubin DI, Hunter G, et al. Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 2000; 35:412-419.
7. Yuh WT, Maley JE. Contrast dosage in the neuroimaging of brain tumors. Magn Reson Imaging Clin N Am 1998; 6:113-124.
8. Runge VM, Kirsch JE, Burke VJ, et al. High dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging 1992; 2:9-18.
9. Mayr NA, Yuh WT, Muhonen MG, et al. Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases. AJNR Am J Neuroradiol 1994; 15:1053-1061.
10. Black WC. High-dose MR in the evaluation of brain metastases: will increased detection decrease cost? AJNR Am J Neuroradiol 1994; 15:1062-1064.
11. Yuh WT, Halloran JI, Mayr NA, Fisher DJ, Nguyen HD, Simonson TM. Dose of contrast material in the MR imaging evaluation of central nervous system tumors. J Magn Reson Imaging 1994; 4:242-249.
12. Yuh WT, Engelken JD, Muhonen MG, Fisher DJ, Erhardt JC. Experience with high dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 1992; 13:335-345.
13. Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ. The effect of contrast dose, imaging time and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995; 16:373-380.
14. Yuh WT, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 1994; 15:1037-1051.
15. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. Invest Radiol 1997; 32:780-796.
16. Kirchin M, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998; 33:798-809.
17. de Haën C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L. Gadobenate dimeglumine 0.5M solution for injection (MultiHance): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999; 23(suppl 1):5161-S168.
18. Adzamli K, Periasamy MP, Spiller M, Koenig SH. NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent. Invest Radiol 1999; 34:410-414.
19. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: phase I studies. Invest Radiol 2002; 37: 706-715.
20. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972; 28:577-584.
21. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measurement 1960; 20:37-46.
22. Finelli DA, Hurst GC, Gullapali RP, Bellon EM. Improved contrast of enhancing brain lesions on post-gadolinium, T1-weighted spin-echo images with use of magnetization transfer. Radiology 1994; 190:553-559.
23. Haustein J, Laniado M, Niendorf HP, et al. Triple dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 1993; 186:855-860.
24. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 2001; 36:72-81.
25. Runge VM, Armstrong MR, Barr RG, et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 2001; 36:65-71.
26. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 2002;37:269-280.
27. Healy ME, Hesselink JR, Press GA, Middleton MS. Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 1987; 165:619-624.
28. Byrne TN. Imaging of gliomas. Semin Oncol 1994; 21:162-171.
29. Runge VM, Muroff LR, Wells JW. Principles of contrast enhancement in the evaluation of brain diseases: an overview. J Magn Reson Imaging 1997; 7:5-13.
30. Schneider G, Kirchin MA, Pirovano G, et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 2001; 14:525-539.
31. Balériaux D, Colosimo C, Ruscalleda J, et al. Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 2002; 44:191-203.
32. Saloman M, Levine H, Rao K. Value of sequentional computed tomography in the multimodality treatment of glioblastoma multiforme. Neurosurgery 1981; 8:15-18.
33. Levin VA, Hoffman WF, Heilbron DC, Norman D. Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. J Neurosurg 1980; 52:642-647.
34. Johnson PC, Hunt SJ, Drayer BP. Human cerebral gliomas: correlation of postmortem MR findings and neuropathologic findings. Radiology 1989; 170:211-217.
35. Ciric I, Vick NA, Mikhael MA, Cozzens J, Eller T, Wash A. Aggressive surgery for malignant supratentorial gliomas. Clin Neurosurg 1990; 36:375-383.
36. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms; dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999; 211:791-798.
37. Cavagna FM, Marzola P, Daprà M, et al. Binding of gadobenate dimeglumine to proteins extravasated into interstitial space enhances conspicuity of reperfused infarcts. Invest Radiol 1994; 29(suppl 2): S50-S53.
38. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol 1978; 19:579-592.
39. Delattre JY, Krol G, Thaler HA, Posner JB. Distribution of brain metastases. Arch Neurol 1988; 45:741-744.
40. Runge VM, Wells JW, Nelson KL, Linville PM. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. J Magn Reson Imaging 1994; 4:669-673.